

**CCHMC INNOVATION FUND/Adare Repurposing Innovation Award**

**2018 Letter of Intent Instructions (LOI)**

Two funding streams are available via the Innovation Fund:

1. CCHMC Innovation Fund (internal funding): The CCHMC Innovation Fund is an internal funding program designed to advance commercially promising technologies. **Grant funds are to be used to enable product development and commercialization.** Examples include the development of prototypes; human clinical data; pre-clinical data; drug delivery platform/systems; large animal studies; algorithmic diagnostics, as opposed to single biomarker associations; or other advanced pre-commercial research. Funds cannot be used for travel expenses; published content (e.g., guidelines, best practices, training manuals); or core services. No more than 15% of the total project budget can be allocated toward PI(s) salaries.

The Innovation Fund will award projects up to $100,000 in direct cost funding for one year, provided the project achieves commercially-viable milestones throughout the duration of the funding period. Renewals for a second $100,000 and an additional 12 months will be considered, assuming mutually agreed upon milestones and deliverables have been met by June 30, 2019, and further work is needed.

1. Adare Repurposing Innovation Award: Adare offers up to $200,000 in funding over two, one-year installments. (Year 2 funding is contingent upon the successful completion of milestones.) Adare is interested in proposals that either optimize or repurpose a known drug for a new indication. Specifically, Adare is interested in studying known therapeutics that could benefit from improved efficacy, improved adverse event/tolerability profiles, improved pharmacokinetic/pharmacodynamic relationships or be developed for an entirely new purpose. Therapeutics must be available for optimizing or repurposing with no more than 5 years of patent exclusivity remaining. **Following completion of the funded research program, Adare will have an exclusive option to enter into a licensing agreement for these projects/intellectual property.**

**Your LOI narrative must be one page or less.** Please include the following information:

* Market potential/opportunity (i.e., potential commercial products or services) of the innovation (value in dollars this innovation will bring – cost savings, time savings, convenience, improved outcomes, applications and market size).
* A brief description of the innovation/problem(s) you are trying to solve including the 1) medical need/research significance; 2) current standard of care/current products and limitations; and 3) plans for ultimate clinical utility (i.e., what is the specific patient population impacted by the technology? What is the ultimate product that will provide a distinct intellectual property or market position?)
* Project objectives (specific aims, development goals).

**Invention disclosure:** PIs are required to submit an invention disclosure form to Innovation Ventures via our [Inventor portal](https://mcinteumprd1.chmccorp.cchmc.org/InteumWeb/inventorportal/login.aspx) for consideration in this program.

**Format:** Please use an 11-point font or larger and one inch margins. The LOI narrative cannot exceed one page in length, single-spaced.

**Submission of LOI:** Please return the cover page and one page LOI, as a single document, to[**Ginny Van Horne**](mailto:virginia.vanhorne@cchmc.org) **by 2:00 p.m. on February 6, 2018.**

**Questions?** Please contact Ginny Van Horne at [Virginia.vanhorne@cchmc.org](mailto:Virginia.vanhorne@cchmc.org) or 513-803-1175.